BRCA2 and ductal breast carcinoma in situ: Notably, the knowledge of a BRCA1/BRCA2 mutation is likely to significantly change the assessment of a DCIS patient's risks for future cancers and the cancer prevention/risk reduction recommendations that would be considered.